NZ731955A - Glycopeptide compositions - Google Patents

Glycopeptide compositions

Info

Publication number
NZ731955A
NZ731955A NZ731955A NZ73195515A NZ731955A NZ 731955 A NZ731955 A NZ 731955A NZ 731955 A NZ731955 A NZ 731955A NZ 73195515 A NZ73195515 A NZ 73195515A NZ 731955 A NZ731955 A NZ 731955A
Authority
NZ
New Zealand
Prior art keywords
acetyl
solutions
amino acid
alanine
glycine
Prior art date
Application number
NZ731955A
Other languages
English (en)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ731955(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of NZ731955A publication Critical patent/NZ731955A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ731955A 2014-11-06 2015-11-06 Glycopeptide compositions NZ731955A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
PCT/EP2015/075918 WO2016071495A1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (1)

Publication Number Publication Date
NZ731955A true NZ731955A (en) 2023-07-28

Family

ID=54478023

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ731955A NZ731955A (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Country Status (30)

Country Link
US (8) US10188697B2 (enExample)
EP (4) EP4147710A1 (enExample)
JP (2) JP6797795B2 (enExample)
KR (2) KR102603756B1 (enExample)
CN (1) CN107073072B (enExample)
AU (1) AU2015341763B2 (enExample)
BR (1) BR112017009405B1 (enExample)
CA (1) CA2964524A1 (enExample)
CL (1) CL2017001139A1 (enExample)
CO (1) CO2017005391A2 (enExample)
CR (1) CR20170234A (enExample)
CY (2) CY1122960T1 (enExample)
DK (2) DK3215173T3 (enExample)
EA (1) EA035368B1 (enExample)
ES (2) ES2852550T3 (enExample)
HR (2) HRP20200101T1 (enExample)
HU (2) HUE049857T2 (enExample)
IL (1) IL252120B (enExample)
MX (1) MX387229B (enExample)
NZ (1) NZ731955A (enExample)
PH (1) PH12017500720A1 (enExample)
PL (2) PL3542812T3 (enExample)
PT (2) PT3215173T (enExample)
RS (2) RS59851B1 (enExample)
SA (1) SA517381446B1 (enExample)
SG (1) SG11201703568WA (enExample)
SI (2) SI3542812T1 (enExample)
TN (1) TN2017000182A1 (enExample)
WO (1) WO2016071495A1 (enExample)
ZA (1) ZA201702767B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3542812T1 (sl) 2014-11-06 2021-04-30 Xellia Pharmaceuticals Aps Glikopeptidni sestavki
EP3393491B1 (en) * 2015-12-24 2025-04-16 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
CN109069580A (zh) * 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 稳定化的糖肽抗生素配制品
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
AU2020237983A1 (en) 2019-03-08 2021-10-07 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US12343373B2 (en) * 2020-10-30 2025-07-01 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (enExample) * 2022-03-08 2023-09-14
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
EP4601615A1 (en) * 2022-10-12 2025-08-20 Hikma Pharmaceuticals USA Inc. Liquid dalbavancin composition
WO2025006267A1 (en) * 2023-06-26 2025-01-02 Venn Biosciences Corporation Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis
GB202405996D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
GB202405997D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
TW457248B (en) 1994-01-28 2001-10-01 Lilly Co Eli Glycopeptide antibiotic derivatives
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
EP1487439A1 (en) * 2002-03-26 2004-12-22 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
JP2006506442A (ja) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物併用療法
CN1826129A (zh) * 2002-07-09 2006-08-30 尖端医疗有限公司 与异亮氨酸硼脯氨酸化合物相关的方法和组合物
HUE041133T2 (hu) 2002-11-18 2019-05-28 Vicuron Pharmaceuticals Llc Dalbavancin adagolási módszer bakteriális fertõzések kezelésére
ES2482700T3 (es) 2005-02-14 2014-08-04 Venus Remedies Limited Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
JP6012716B2 (ja) * 2011-05-19 2016-10-25 サヴァラ，インク． 乾燥粉末バンコマイシン組成物および関連する方法
US20150182667A1 (en) 2012-08-08 2015-07-02 Vanderbilt University Composition with Biofilm Dispersal Agents
ES2743039T3 (es) * 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) * 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
WO2015138983A1 (en) 2014-03-14 2015-09-17 Cutispharma, Inc. Composition and method for vancomycin oral liquid
SI3542812T1 (sl) * 2014-11-06 2021-04-30 Xellia Pharmaceuticals Aps Glikopeptidni sestavki
CN109069580A (zh) 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 稳定化的糖肽抗生素配制品
US12343373B2 (en) 2020-10-30 2025-07-01 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
WO2016071495A1 (en) 2016-05-12
US20230158101A1 (en) 2023-05-25
AU2015341763A1 (en) 2017-06-08
HRP20210342T8 (hr) 2022-01-21
IL252120B (en) 2020-07-30
EP4147710A1 (en) 2023-03-15
JP6797795B2 (ja) 2020-12-09
HUE049857T2 (hu) 2020-10-28
US12161690B2 (en) 2024-12-10
ES2852550T3 (es) 2021-09-13
US20200069768A1 (en) 2020-03-05
KR102763211B1 (ko) 2025-02-04
US11628200B2 (en) 2023-04-18
BR112017009405B1 (pt) 2024-02-06
US20190160142A1 (en) 2019-05-30
IL252120A0 (en) 2017-07-31
CR20170234A (es) 2018-01-15
MX387229B (es) 2025-03-04
US20250288640A1 (en) 2025-09-18
TN2017000182A1 (en) 2018-10-19
PL3215173T3 (pl) 2020-05-18
CA2964524A1 (en) 2016-05-12
US20180133286A1 (en) 2018-05-17
HUE053347T2 (hu) 2021-06-28
EP3542812A1 (en) 2019-09-25
US20220354927A1 (en) 2022-11-10
SG11201703568WA (en) 2017-05-30
US20210220433A1 (en) 2021-07-22
CL2017001139A1 (es) 2017-12-01
DK3215173T3 (da) 2020-03-23
US10188697B2 (en) 2019-01-29
US10849956B2 (en) 2020-12-01
ES2769849T3 (es) 2020-06-29
PT3215173T (pt) 2020-04-03
EP3215173A1 (en) 2017-09-13
HRP20200101T1 (hr) 2020-04-03
KR102603756B1 (ko) 2023-11-16
CY1124011T1 (el) 2022-05-27
EP3215173B1 (en) 2020-01-01
US20170348385A1 (en) 2017-12-07
PH12017500720A1 (en) 2017-10-09
AU2015341763B2 (en) 2019-01-17
EA201790997A1 (ru) 2017-09-29
HRP20210342T1 (hr) 2021-04-30
BR112017009405A2 (pt) 2018-01-02
SI3215173T1 (sl) 2020-03-31
RS59851B1 (sr) 2020-02-28
SI3542812T1 (sl) 2021-04-30
EP3215173B8 (en) 2020-03-11
KR20230096142A (ko) 2023-06-29
JP7032488B2 (ja) 2022-03-08
EP3834837A1 (en) 2021-06-16
CY1122960T1 (el) 2021-10-29
RS61418B1 (sr) 2021-03-31
EA035368B1 (ru) 2020-06-03
PL3542812T3 (pl) 2021-07-12
SA517381446B1 (ar) 2020-09-21
US11000567B2 (en) 2021-05-11
US10039804B2 (en) 2018-08-07
MX2017005749A (es) 2018-01-11
ZA201702767B (en) 2018-12-19
US11517609B2 (en) 2022-12-06
DK3542812T3 (da) 2021-04-12
KR20170078830A (ko) 2017-07-07
CN107073072A (zh) 2017-08-18
PT3542812T (pt) 2021-04-20
JP2017533218A (ja) 2017-11-09
EP3542812B1 (en) 2021-01-13
JP2020183424A (ja) 2020-11-12
CN107073072B (zh) 2021-06-18
CO2017005391A2 (es) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12017500720A1 (en) Glycopeptide compositions
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016005395A (es) Formulacion estable de insulina glulisina.
EP3255042A4 (en) Heterocyclic compound and pharmaceutical composition comprising same
UA115357C2 (uk) Похідні піридин-4-ілу
TW201613557A (en) Stable aqueous recombinant protein formulations
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
PT3737470T (pt) Derivados do ácido 3-fenil-4-hexinoico como agonistas de gpr40
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
WO2014145314A3 (en) Methods and compositions for gamma-glutamyl cycle modulation
EP3239165A4 (en) Composition containing nitrogen heterocyclic hexapeptide precursor and preparation method and application thereof
GEP20186879B (en) Cycloalkyl-linked diheterocycle derivatives
PH12014501384A1 (en) Antibiotic formulations
EP3135299A4 (en) Active ingredient (i) containing composition and method for preparing same
EP3253202A4 (en) Acid herbicide-containing compositions, precursors, derivatives, and methods
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
MY180369A (en) Pharmaceutical composition for external use
EP3281932A4 (en) Composition containing acrylic acid derivative, and method for stabilizing acrylic acid derivative
UA106905U (uk) Фармацевтична композиція
EP3281935A4 (en) Acrylic acid derivative-containing composition, and method for stabilizing acrylic acid derivative
UA92173U (ru) Фармацевтическая композиция для применения в ветеринарии

Legal Events

Date Code Title Description
PSEA Patent sealed
ASS Change of ownership

Owner name: HIKMA PHARMACEUTICALS USA INC., US

Effective date: 20241121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2025 BY NASIM

Effective date: 20241030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2026 BY SABINE BRANDL

Effective date: 20251101